Abstract:Background: In patients with chemotherapy-induced anemia (CIA), erythropoiesis stimulating agents (ESAs) are effective but are associated with potentially serious side effects, such as venous thromboembolism (VTE). The addition of iron to ESA therapy improves hematologic response, reduces risk of red cell transfusion, and is well tolerated (Mhaskar 2016). This raises the question as to whether intravenous (IV) iron alone accomplishes the same goals in patients with cancer (PwC). Several observational studies evaluating IV iron monotherapy in PwC receiving chemotherapy have demonstrated increases in hemoglobin (Hb) concentrations and/or reductions in transfusion rates, (Dangsuwan 2010, Kim 2007, Hedenus 2014) suggesting that IV iron monotherapy is a feasible treatment option for patients with CIA. However, prospective, randomized, placebo-controlled trial data evaluating the effect of IV iron in PwC and CIA has yet to be produced. This is the first randomized study to prospectively evaluate the safety and efficacy of an IV iron replacement therapy (ferric carboxymaltose (FCM; Injectafer), as monotherapy for patients with CIA. Design/Methods : This 18-week, double-blind, phase 3 study included adults >18 years of age with CIA receiving chemotherapy (≥4 weeks' treatment remaining) for a non-myeloid malignancy. Inclusion criteria included: (Hb) 8-11 g/dL, ferritin 100-800 ng/mL, and transferrin saturation (TSAT) ≤35%; an Eastern Cooperative Oncology Group Performance Status [ECOG PS] score of 0-2; and life expectancy ≥6 months. PwC were excluded if they received oral or IV iron, RBC transfusion, or ESAs within 4 weeks of screening; iron-containing multivitamins were permitted. Study patients were randomized 1:1 to receive IV FCM or IV placebo. FCM was administered as two 15-minute infusions each separated by 7 days, each at a dose of 15 mg/kg (maximum single dose: 750 mg [total dose ≤1500 mg] diluted in ≤250 mL saline). For blinding purposes, placebo was normal saline ≤250 mL, administered as covered 15-minute infusions. Patients were randomized 1:1 to receive FCM or placebo. The primary efficacy endpoint was percentage of patients with a decrease in Hb ≥0.5 g/dL from weeks 3 to 18; the secondary efficacy endpoint was change in Hb from baseline to end of treatment. Based on the assumption that 65% of patients in the placebo group and 42% of patients in the FCM group would not maintain baseline Hb concentrations, it was determined that 106 PwC were needed in each treatment group to provide 90% power to detect a statistically significant difference in the primary endpoint measured using a continuity-corrected 2-sided chi-squared test at a significance level of α=0.05. Results: The study randomized 244 PwC (n=122, both groups). The percentage of patients with a decrease in Hb ≥0.5 g/dL from weeks 3 to 18 was significantly lower with FCM versus placebo (35.3% vs 50.8%; odds ratio=0.51, P=0.01). Improvements from baseline Hb to end of treatment were not significantly different between FCM and placebo (1.04 vs 0.87 g/dL), but were greater with FCM in a subgroup of patients with baseline Hb <10 g/dL (P=0.01). The percentage of patients in the subgroup had an increase from baseline Hb of ≥1 g/dL (71% vs 54%, respectively; P=0.01) and a shorter median time to Hb increase of ≥1 g/dL (43 vs 85 days; P=0.001) versus placebo. The most common adverse events (AEs) were neutropenia (17% vs 12%), hypophosphatemia (16% vs 3%), and fatigue (15% vs 14%; FCM vs. placebo, respectively). VTE did not occur in any PwC in either arm. In general, FCM raised no safety signals and was well tolerated, with no notable difference between groups in the incidence of AEs other than hypophosphatemia. A decrease in serum phosphate (ie < 2.0 mg/dL) from Day 7 to Week 3 was seen in up to 38% of patients receiving FCM, however this did not produce any symptoms in affected patients. No differences were found between the FCM and placebo groups who received non-study interventions (22 [18%] vs 25 [21%], respectively), including those requiring blood transfusions (15 [13%] vs 14 [12%]). Conclusion: In this phase 3 trial of patients with CIA, Hb was maintained within ≥0.5 g/dL of baseline from weeks 3 to 18 in patients in 64.7% receiving FCM and 49.2% receiving placebo. Additionally, FCM maintained Hb for up to 18 weeks for the majority of PwC and CIA, and did not increase the risk for VTE. Disclosures Boccia: AMAG: Consultancy; AstraZeneca: Speakers Bureau; Amgen: Speakers Bureau; Celgene: Speakers Bureau; DSI: Speakers Bureau; Genentech: Speakers Bureau. Krupa:American Regent: Employment. OffLabel Disclosure: Unsure: This study discusses parenteral iron for chemotherapy-induced anemia. Currently, no IV iron product has a labeled indication for this specific patient population, however ferric carboxymaltose is indicated for adults who have intolerance to oral iron or have had unsatisfactory response to oral iron or adults who have non-dialysis dependent chronic kidney disease.

Clinical Efficacy and Safety of Intravenous Ferric Carboxymaltose for Treatment of Restless Legs Syndrome: A Multicenter, Randomized, Placebo-controlled Clinical Trial

A randomized double‐blind pilot study to evaluate the efficacy, safety, and tolerability of intravenous iron versus oral iron for the treatment of restless legs syndrome in patients with iron deficiency anemia

A Randomized, Controlled, Open Label Non-Inferiority Trial of Intravenous Ferric Carboxymaltose Versus Iron Sucrose in Patients with Iron Deficiency Anemia in China.

Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.

Efficacy Of The Low-Dose Saccharum Iron Treatment Of Idiopathic Restless Legs Syndrome

Efficacy and Safety of Ferric Carboxymaltose Injection in Reducing Anemia in Patients Receiving Chemotherapy for Non-Myeloid Malignancies: A Phase 3, Placebo-Controlled Study (IRON CLAD)

Efficacy of intravenous ferric carboxymaltose for iron deficiency following acute heart failure (AHF) in patients with previously diagnosed HF: a subgroup analysis of AFFIRM-AHF

Efficacy of Ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis

Changes in myocardial iron content following administration of intravenous iron (Myocardial‐IRON): Study design

Peripheral Iron Metabolism is Associated with Leg Movements on Polysomnography but Not with the Severity of Restless Legs Syndrome or Its Impact on Patients

Randomized pilot trial for the efficacy of the MMF07 foot massager and heat therapy for restless legs syndrome

A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric Derisomaltose (FDI)) in Iron deficient but not anaemic patients with chronic kidney disease on functional status

0807 Ferric Carboxymaltose versus Iron Sucrose for Pediatric Sleep-related Movement Disorders

Effects of Dietary Supplementation in Patients with Restless Legs Syndrome: A Systematic Review

Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial

Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial

Ferric Carboxymaltose in Iron-Deficient Patients with Hospitalized Heart Failure and Reduced Kidney Function

Randomized controlled trial of Intravenous ferric-carboxymaltose vs oral iron to treat iron deficiency anemia after variceal bleed in patients with cirrhosis

Characterization of serum phosphate levels over time with intravenous ferric carboxymaltose versus placebo as treatment for heart failure with reduced ejection fraction and iron deficiency: An exploratory prospective substudy from HEART‐FID

Treating Severe Refractory and Augmented Restless Legs Syndrome

P567 Impact of oral ferric maltol and IV iron on health-related quality of life in patients with iron deficiency anaemia and inflammatory bowel disease, and relationship with haemoglobin and serum iron